Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

Research Grant to Fund Development of Novel Tumor-Imaging Nanoprobes

By BiotechDaily International staff writers
Posted on 04 Nov 2013
Research funds have been awarded that will support a collaborative effort to develop novel nanoprobes to be used for in vivo tumor imaging.

Rockland Immunochemicals Inc. (Gilbertsville, PA, USA) and Abzyme Therapeutics (Malvern, PA, USA) have received a Phase I Small Business Innovation Research (SBIR) grant from the [US] National Cancer Institute (Bethesda, MD, USA) to develop nanoprobes for in vivo imaging of tumors that express the important cancer therapeutic targets: EGFR (epidermal growth factor receptor), Her2 (human epidermal growth factor receptor 2), or mesothelin.

According to the terms of the grant, during the first phase the partners will develop, label, and characterize high-affinity single domain antibodies against the three tumor antigens. Abzyme Therapeutics will develop the single domain antibodies, and Rockland will be responsible for bioconjugation and in vivo characterization.

In the planned second phase of the project, the key antibodies will be labeled with a radioactive isotope and characterized using PET scanners in collaboration with Yale University (New Haven, CT, USA) and the University of Pittsburg (PA, USA). Suitable radioactively labeled antibodies will be used as in vivo imaging agents, and their potential use in targeted cancer therapy will be considered.

“In these times of shrinking government investment in research, this SBIR grant validates Rockland’s business model of collaboration with leading academic institutions to aggregate, develop, and commercialize technologies that will ultimately benefit humanity,” said Jim Fendrick, president and CEO of Rockland Immunochemicals. “This research is in line with the company’s expertise in antibodies and antibody based tools. We are confident that this collaboration will generate significant innovation and that the results will have great scientific and commercial applications.”

According to the market research firm Markets and Markets (Pune, India), the global diagnostic imaging market, which stood at USD 20.7 billion in 2010, is expected to expand to USD 26.6 billion by 2016. This expected rise is attributed to an aging population, increasing awareness about preventive care, and advancements in the field.

Related Links:
Rockland Immunochemicals Inc.
Abzyme Therapeutics
[US] National Cancer Institute




Channels

Genomics/Proteomics

view channel
Image: The photo shows a mouse pancreatic islet as seen by light microscopy. Beta cells can be recognized by the green insulin staining. Glucagon is labeled in red and the nuclei in blue (Photo courtesy of Wikimedia Commons).

Regenerative Potential Is a Trait of Mature Tissues, Not an Innate Feature of Newly Born Cells

Diabetes researchers have found that the ability of insulin-producing beta cells to replicate and respond to elevated glucose concentrations is absent in very young animals and does not appear until after weaning.... Read more

Drug Discovery

view channel
Image: Wafers like the one shown here are used to create “organ-on-a-chip” devices to model human tissue (Photo courtesy of Dr. Anurag Mathur, University of California, Berkeley).

Human Heart-on-a-Chip Cultures May Replace Animal Models for Drug Development and Safety Screening

Human heart cells growing in an easily monitored silicon chip culture system may one day replace animal-based model systems for drug development and safety screening. Drug discovery and development... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.